Trial Profile
Phase I dose escalation study of MB311 in cancer patients with malignant effusions
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Mar 2016
Price :
$35
*
At a glance
- Drugs MB 311 (Primary)
- Indications Cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Meridian Biopharmaceuticals
- 21 Mar 2016 Results published in company's website.
- 21 Mar 2016 New trial record